-
CancelDate：2021-04
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=566Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (“BlissBio”) announces the completion of over 400M CNY Series-B financing round. The financing was led by GL Ventures, the venture capital unit of Hillhouse Capital, with participation from Cormorant Asset Management, VMS Group, and Heda Biopharmaceutical Venture Capital. The Series B financing round was also supported by existing investors, Sherpa Healthcare Partners and Oriental Fortune Capital. CEC Capital Group acted as the exclusive financial advisor in the transaction.
-
Cancel -
CancelDate：2021-04
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=561Arrail Group (“Arrail” or the “Company), a leading dental service provider in China, announced that it has closed its Series E financing, with a transaction value of nearly $200M. The transaction was led by Temasek, with participation from OrbiMed, Ward Ferry, Hina Group, Industrial Bank and Mirae Asset. CEC Capital Group was the exclusive financial advisor on this transaction, and is proud to have advised Arrail since its Series A round of financing.
-
CancelDate：2021-04
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=818The innovative artificial joint company b-ONE successfully closed a B-round financing of several hundred of million RMB, marking it the the largest RMB financing in the domestic orthopedic joint sector in recent years. The funding was led by Huatai Zijin
-
CancelDate：2021-04
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=819On April 12, SUNING LSY announced the successful closing of a significant Series A financing with investment from CPE and ADV Partners. CEC Capital Group served as the exclusive financial advisor in this transaction for SUNING LSY.
-
CancelDate：2021-03
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=560PALO ALTO, CA, March 30, 2021 -- Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints today announced the closing of a $73 million Series B1/2 financing. The round was led by Oceanpine Capital with participation from additional new investors including Octagon Capital and Sphera Funds Management, and existing investors, including Northern Light Venture Capital and Vivo Capital. In addition, the company received a strategic capital investment from The Leukemia & Lymphoma Society’s Therapy Acceleration Program? (LLS TAP), directed toward advancing the company’s work to treat blood cancers. CEC Capital Group was the exclusive financial advisor on this transaction.
-
CancelDate：2021-03
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=821HISTO, the first independent third-party pathology diagnostic center in China, recently announced the closing of its B round financing, raising over RMB 100 million. The round was led by Haier Medical with participation from Flyfot Ventures and other well
-
CancelDate：2021-03
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=822Shanghai Cell Therapy Group, a leading player in the cell therapy industry in China, has announced the successful closing of its Series D1 financing, raising nearly RMB 500 million. The round was jointly invested by Jiuzhou Venture, Sun Rock Capital, and
-
CancelDate：2021-03
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=823Thousand Oaks, a rapidly growing Contract Development and Manufacturing Organization (CDMO) and cell culture biotechnology company, announced today that it has raised over RMB 400 million in its Series C Financing in March 2021. This round of financing wa
Scan to log in to WeChatLog in on phone to use WeChat on Web
京公網安備 11010102004518號